Clinical and retrospective studies indicate that GLP-1 receptor agonists like Ozempic (semaglutide) are associated with reductions in bone mineral density driven primarily by weight loss, though some experimental and genetic studies suggest these effects may be modest or comparable to weight-loss-induced unloading rather than a direct toxic effect on bone.
The evidence we hold leans leans supported
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x
The retrieved literature contains conflicting evidence regarding the effects of GLP-1 receptor agonists (such as semaglutide and tirzepatide) on bone health. Several clinical and retrospective studies (e.g., Liu et al., and the 2026 retrospective study on semaglutide and tirzepatide) report significant decreases in bone mineral density associated with treatment and weight loss. Conversely, controlled animal comparisons (such as the mouse study showing semaglutide preservation compared to bariatric surgery) and Mendelian randomization analyses find no direct causal link between GLP-1 receptor expression and bone loss. Therefore, the evidence is CONTESTED.